Rhamnazin

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Rhamnazin 是一种具有口服活性的 VEGFR2 信号通路抑制剂，对 VEGFR2 激酶的 IC50 为 4.68 μM。Rhamnazin 具有较强的抗血管生成活性和抗肿瘤作用。Rhamnazin 具有抗氧化和抗炎作用。

Rhamnazin is an orally active inhibitor of VEGFR2 signaling with an IC50 of 4.68 μM against VEGFR2 kinase. Rhamnazin shows potent antiangiogenic activity and antitumor efficacy. Rhamnazin shows antioxidant and anti-inflammatory properties.

Rhamnazin (200 mg/kg; i.g.; daily for 25 days) 抑制小鼠乳腺癌生长和血管生成。Rhamnazin (5-20 mg/kg; i.p.; once) 在大鼠急性肺损伤模型中显示出较强的抗氧化和抗炎作用。Animal Model:BALB/c nude mice, breast cancer xenograft model Dosage:200 mg/kg Administration:Intragastric administration, daily for 25 days Result:Dramatically suppressed tumor volumes by 47% compared with the vehicle group. Showed a significant reduction of pVEGFR2Tyr951-positive cells in tumors. Resulted in downregulation of VEGFR2 downstream molecules phosphorylation including MAPK, AKT and STAT3.

Rhamnazin (5-40 μM) 抑制 VEGF 诱导的 HUVECs 增殖、迁移和成管。Rhamnazin (0-20 μM) 降低 VEGFR-2 酪氨酸激酶活性和 VEGFR-2 信号通路。Rhamnazin (0-40 μM; 24 h) 抑制乳腺癌细胞增殖和 VEGFR2 信号通路。Cell Migration Assay Cell Line:HUVECs Concentration:0, 10, 15 and 20 μM Incubation Time:6 h Result:Strongly inhibited the migration of HUVECs.Western Blot Analysis Cell Line:HUVECs Concentration:0, 10, 15 and 20 μM Incubation Time:24 h Result:Decreased VEGF binding to VEGFR2. Reduced VEGF-stimulated phosphorylation of VEGFR2 and its downstream MAPK, AKT, and STAT3 in HUVECs in a concentrationdependent manner.Cell Proliferation Assay Cell Line:HCC1937, T-47D, SK-BR-3, MCF-7 and MDA-MB-231 Concentration:0, 10, 15, 20, 30 and 40 μM Incubation Time:24 h Result:Inhibited cell growth with IC50s of 19, 27, 32, 41 and 64 μM against MDA-MB-231, MCF-7, SK-BR-3, T-47D and HCC1937 in the presence of VEGF, respectively.

鼠李秦素

Others

Other Targets

Others

———

———

552-54-5

330.29

C17H14O7

>98% (HPLC)

———

O=C1C(O)=C(OC2=CC(OC)=CC(O)=C12)C=3C=CC(O)=C(OC)C3

O=C1C(O)=C(OC2=CC(OC)=CC(O)=C12)C=3C=CC(O)=C(OC)C3

(-20℃)

With Ice Pack

≥ 2 years